EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel Acetamide-Based HO-1 Inhibitor Counteracts Glioblastoma Progression by Interfering with the Hypoxic–Angiogenic Pathway

Agata Grazia D'Amico, Grazia Maugeri iD, Luca Vanella iD, Valeria Consoli iD, Valeria Sorrenti iD, Francesca Bruno iD, Concetta Federico iD, Antonino Nicolò Fallica iD, Valeria Pittalà iD, Velia D'Agata iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25105389 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Agata Grazia D'Amico und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug and Health Sciences, University of Catania, 95125 Catania, Italy. Hauptthemen laut MEDLINE: Glioblastoma, Heme Oxygenase-1, Acetamides, Vascular Endothelial Growth Factor A. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Programma Ricerca di Ateneo Pia.Ce.Ri 2020-2022 linea 2, project number 57722172126, Programma Ricerca di Ateneo Pia.Ce.Ri 2020-2022 linea 3, STARTING GRANT 2020 project number 57722172133, University of Catania.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma multiforme (GBM) represents the deadliest tumor among brain cancers. It is a solid tumor characterized by uncontrolled cell proliferation generating the hypoxic niches in the cancer core. By inducing the transcription of hypoxic inducible factor (HIF), hypoxia triggers many signaling cascades responsible for cancer progression and aggressiveness, including enhanced expression of vascular endothelial growth factor (VEGF) or antioxidant enzymes, such as heme oxygenase-1 (HO-1). The present work aimed to investigate the link between HO-1 expression and the hypoxic microenvironment of GBM by culturing two human glioblastoma cell lines (U87MG and A172) in the presence of a hypoxic mimetic agent, deferoxamine (DFX). By targeting hypoxia-induced HO-1, we have tested the effect of a novel acetamide-based HO-1 inhibitor (VP18/58) on GBM progression. Results have demonstrated that hypoxic conditions induced upregulation and nuclear expression of HO-1 in a cell-dependent manner related to malignant phenotype. Moreover, our data demonstrated that the HO-1 inhibitor counteracted GBM progression by modulating the HIFα/HO-1/VEGF signaling cascade in cancer cells bearing more malignant phenotypes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaHeme Oxygenase-1AcetamidesVascular Endothelial Growth Factor ASignal TransductionHumansCell Line, TumorBrain NeoplasmsNeovascularization, PathologicCell ProliferationDisease ProgressionHypoxia-Inducible Factor 1, alpha SubunitGene Expression Regulation, NeoplasticCell Hypoxia

Stichwörter der Autor:innen

HO-1 geneHO-1 inhibitorsangiogenesisglioblastoma multiformehypoxiavascular endothelial growth factor

Substanzen

Heme Oxygenase-1AcetamidesVascular Endothelial Growth Factor AHMOX1 protein, humanHypoxia-Inducible Factor 1, alpha SubunitacetamideVEGFA protein, human

Autor:innen und Institutionen

  • Department of Drug and Health Sciences, University of Catania, 95125 Catania, Italy.
  • Department of Biomedical and Biotechnological Sciences, Section of Anatomy, Histology and Movement Sciences, University of Catania, 95100 Catania, Italy.
  • Department of Biological, Geological and Environmental Sciences, Section of Animal Biology, University of Catania, 95123 Catania, Italy.
  • Department of Molecular Medicine, College of Medicine and Medical Sciences, Princess Al-Jawhara Centre for Molecular Medicine, Arabian Gulf University, Manama 329, Bahrain.

ORCID-Profile: Grazia Maugeri, Luca Vanella, Valeria Consoli, Valeria Sorrenti, Francesca Bruno, Concetta Federico, Antonino Nicolò Fallica, Valeria Pittalà, Velia D'Agata

Förderung

  • Programma Ricerca di Ateneo Pia.Ce.Ri 2020-2022 linea 2, project number 57722172126
  • Programma Ricerca di Ateneo Pia.Ce.Ri 2020-2022 linea 3, STARTING GRANT 2020 project number 57722172133
  • University of Catania

Zitieren

APA

D'Amico, A. G., Maugeri, G., Vanella, L., Consoli, V., Sorrenti, V., Bruno, F., Federico, C., Fallica, A. N., Pittalà, V., & D'Agata, V. (2024). Novel Acetamide-Based HO-1 Inhibitor Counteracts Glioblastoma Progression by Interfering with the Hypoxic–Angiogenic Pathway. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25105389

Vancouver

D'Amico AG, Maugeri G, Vanella L, Consoli V, Sorrenti V, Bruno F, et al. Novel Acetamide-Based HO-1 Inhibitor Counteracts Glioblastoma Progression by Interfering with the Hypoxic–Angiogenic Pathway. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25105389

BibTeX
@article{DAmico2024,
  author = {D'Amico, Agata Grazia and Maugeri, Grazia and Vanella, Luca and Consoli, Valeria and Sorrenti, Valeria and Bruno, Francesca and Federico, Concetta and Fallica, Antonino Nicolò and Pittalà, Valeria and D'Agata, Velia},
  title = {Novel Acetamide-Based HO-1 Inhibitor Counteracts Glioblastoma Progression by Interfering with the Hypoxic–Angiogenic Pathway},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25105389}
}
Kostenlos starten →